Sergliflozin etabonate

 Sergliflozin etabonate (INN/USAN,[1][2] codenamed GW869682X) is an investigational anti-diabetic drug being developed by GlaxoSmithKline. It did not undergo further development after phase II.[citation needed]

Sergliflozin etabonate
Sergliflozin etabonate 2.svg
Clinical data
Routes of
administration		Oral
ATC code
  • none
Identifiers
IUPAC name
  • 2-(4-methoxybenzyl)phenyl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside
CAS Number
  • 408504-26-7 check
PubChem CID
  • 9824918
IUPHAR/BPS
  • 4587
ChemSpider
  • 21234810 ☒
UNII
  • 4HY3523466
ChEMBL
  • ChEMBL450044 ☒
CompTox Dashboard (EPA)
  • DTXSID20961265 Edit this at Wikidata
Chemical and physical data
FormulaC23H28O9
Molar mass448.468 g·mol−1
3D model (JSmol)
  • Interactive image
SMILES
  • CCOC(=O)OCC1C(C(C(C(O1)Oc2ccccc2Cc3ccc(cc3)OC)O)O)O
InChI
  • InChI=1S/C23H28O9/c1-3-29-23(27)30-13-18-19(24)20(25)21(26)22(32-18)31-17-7-5-4-6-15(17)12-14-8-10-16(28-2)11-9-14/h4-11,18-22,24-26H,3,12-13H2,1-2H3 ☒
  • Key:QLXKHBNJTPICNF-UHFFFAOYSA-N ☒
 ☒check (what is this?)  (verify)

Method of actionEdit

Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[3][4]

ChemistryEdit

Etabonate refers to the ethyl carbonate group. The remaining structure, which is the active substance, is called sergliflozin.

Sergliflozin

This article uses material from the Wikipedia article
 Metasyntactic variable, which is released under the 
Creative Commons
Attribution-ShareAlike 3.0 Unported License.